Lillian Siu, MD
Princess Margaret Cancer Centre
12
12
3
N/A
0
13
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (12)
Showing 10 of 12 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Scott Bratman, MD
Princess Margaret Cancer Centre
Shared therapeutic areas:
Worked with same sponsors:
Anna Spreafico, MD
Princess Margaret Cancer Centre
Shared therapeutic areas:
Worked with same sponsors:
Bedard Philippe, MD
Princess Margaret Cancer Centre
Shared therapeutic areas:
Worked with same sponsors:
Kyaw Aung, MD
Princess Margaret Cancer Centre
Shared therapeutic areas:
Worked with same sponsors:
Daniel Renouf, MD
British Columbia Cancer Agency
Shared therapeutic areas:
Worked with same sponsors:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
Shared therapeutic areas:
Aminah Jatoi, MD
Mayo Clinic
Shared therapeutic areas:
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Norman Wolmark, MD
NSABP Foundation Inc
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (12)
Showing 12 of 12 trials
A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
Immune Resistance Interrogation Study
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients
Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples
Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
All 12 trials loaded